A detailed history of Exane Derivatives transactions in Ptc Therapeutics, Inc. stock. As of the latest transaction made, Exane Derivatives holds 12 shares of PTCT stock, worth $485. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12
Previous 128 90.63%
Holding current value
$485
Previous $4,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 12, 2022

SELL
$25.6 - $45.23 $2,969 - $5,246
-116 Reduced 90.63%
12 $0
Q1 2022

Apr 22, 2022

SELL
$33.33 - $44.6 $1,133 - $1,516
-34 Reduced 20.99%
128 $4,000
Q4 2021

Jan 28, 2022

SELL
$35.36 - $41.86 $40,239 - $47,636
-1,138 Reduced 87.54%
162 $6,000
Q3 2021

Oct 26, 2021

SELL
$37.01 - $44.74 $10,436 - $12,616
-282 Reduced 17.83%
1,300 $48,000
Q4 2020

Jan 27, 2021

SELL
$47.96 - $67.64 $96,351 - $135,888
-2,009 Reduced 55.95%
1,582 $96,000
Q3 2020

Oct 06, 2020

BUY
$45.41 - $57.07 $86,279 - $108,433
1,900 Added 112.36%
3,591 $167,000
Q1 2020

Apr 17, 2020

SELL
$32.37 - $59.36 $8,124 - $14,899
-251 Reduced 12.92%
1,691 $75,000
Q4 2019

Jan 22, 2020

BUY
$32.22 - $50.07 $62,571 - $97,235
1,942 New
1,942 $93,000

Others Institutions Holding PTCT

About PTC THERAPEUTICS, INC.


  • Ticker PTCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,541,000
  • Market Cap $2.9B
  • Description
  • PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on...
More about PTCT
Track This Portfolio

Track Exane Derivatives Portfolio

Follow Exane Derivatives and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.